Remove Drugs Remove Small Molecule Remove Synthetic Chemistry
article thumbnail

Re-Imagining Med Chem Strategies: the Tyranny of the n+1 Compound

DrugBaron

Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. Yet the situation with small molecules is even worse.

article thumbnail

Part 2 Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis - Recap

The Strateos Blog: Drug Discovery

On September 15th, Strateos hosted Part 2 of its Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis. Ben Miles, Ph.D., Head of Product Management at Strateos was joined by Josh Bond, Director of Product Management at PerkinElmer Informatics to discuss this exciting collaboration. Ben Miles, Ph.D.,

article thumbnail

Following our pole star to a transformative collaboration

Dark Matter Blog

The second is that while it may be hard to achieve molecular recognition, it’s even harder to make a drug, which is to say a molecule that you can eat, that distributes throughout the body, and survives long enough to find its target. Consequently, we were going to stick to chemical space where we know real drugs live.

RNA 52
article thumbnail

AWS helps Pfizer accelerate drug development and clinical manufacturing

The Pharma Data

As a result, Pfizer can maximize uptime for equipment such as centrifuges, agitators, pulverizers, coaters, and air handlers used in clinical drug manufacturing. The overall focus of this collaboration is to support Pfizer in more rapidly and reliably producing new drugs and evaluating their potential health benefit for patients.

article thumbnail

Drug Discovery and Medicinal Chemistry in the Era of Automation - Webinar Recap

The Strateos Blog: Drug Discovery

On July 20th, Strateos hosted a webinar entitled Drug Discovery and Medicinal Chemistry in the Era of Automation. To advance a lead candidate through to clinical trials in traditional small molecule pipelines, it can take on average 6+ years. Daniel Rines, Ph.D., Director of R&D Strategy and Vince Yeh, Ph.D.,

article thumbnail

Highlights from SLAS 2022 Conference - Event Recap

The Strateos Blog: Drug Discovery

Strateos’ SVP of Strategy & Operations, Daniel Sipes, echoed this sentiment during his presentation on how automated labs are accelerating medicinal chemistry (MedChem) cycles for drug discovery. The model quality data generated is well-suited to support AI and machine learning tools.”